Elemental reducing agents for critical care treatment to prevent cardiac and skeletal muscle loss: lead candidate FDY-5301 Ph 3 (pivotal) to initiate mid-2020 for reperfusion injury following heart attack (AMI); data early 2023. SPA submission received by FDA Jan 22, 2020 and initial feedback received Feb 2020 - Type A meeting requested. Ph 2 recruitment completed for muscle weakness following total knee replacement; data in 1Q20. Ph 2 ready for ICU-acquired weakness following trauma; first patient dosed expected 2Q20. Significant additional treatment applications with limited to no competition. $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage
US - Pacific
1616 Eastlake Ave E
Seattle, WA 98102
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.